| 0 (0%) | 11-11 19:21 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.25 | 1-year : | 23.59 |
| Resists | First : | 18.19 | Second : | 20.2 |
| Pivot price | 16.63  |
|||
| Supports | First : | 14.94 | Second : | 12.43 |
| MAs | MA(5) : | 15.62 |
MA(20) : | 16.9 |
| MA(100) : | 16.29 |
MA(250) : | 17.23 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 15.5 |
| RSI | RSI(14): 32.5 |
|||
| 52-week | High : | 25 | Low : | 13.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PLSE ] has closed above bottom band by 11.2%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.95 - 16.07 | 16.07 - 16.15 |
| Low: | 14.89 - 15.03 | 15.03 - 15.15 |
| Close: | 15.12 - 15.32 | 15.32 - 15.47 |
Tue, 11 Nov 2025
PLSE to Participate in Oppenheimer Virtual Event This November - GuruFocus
Mon, 10 Nov 2025
Pulse Biosciences (PLSE) Is Down 7.9% After FDA OK for Cardiac Device Trials and Q3 Losses – Has the Bull Case Changed? - Yahoo Finance
Mon, 10 Nov 2025
Price momentum metrics for PLSE explained - 2025 Pullback Review & Expert Approved Momentum Ideas - newser.com
Fri, 07 Nov 2025
Pulse Biosciences (PLSE): Evaluating Valuation After Recent Share Price Decline - Sahm
Fri, 07 Nov 2025
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 06 Nov 2025
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 67 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 74.2 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 2,450 (K) |
| Shares Short P.Month | 2,540 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.2 % |
| Return on Equity (ttm) | -103.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -14.19 |
| PEG Ratio | 0 |
| Price to Book value | 9.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -23.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|